Message #79 From:
NewsBot Date: December 8, 2006 05:30:00 AM
MIVT News MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation Reiterated In Research Note By Investrend Affiliate SISM Research, Indicating Greater Market Potential And Citing Recent Superior Performance of Stent Coating Technologies In Recent Tests
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst
with Investrend affiliate SISM Research and a four star analyst
according to StarMine, has reiterated his “Buy/4”
Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc.
(OTCBB: MIVT) in a Research Note.
“Just last Wednesday, MIVT announced
remarkable results from preclinical studies of two of its novel
biocompatible polymer-free drug-eluting stent coating technologies that
matched or even outperformed Cordis’ and
Boston Scientific’s drug eluting stents. The
independently conducted four-week porcine study at the Erasmus
University Medical Center in the Netherlands compared stents coated with
MIVT's polymer-free drug-eluting technologies to the industry's
benchmark, the J&J Cypher stent, one of the world's best selling
drug-eluting stents. Three variations of MIVT's polymer-free Sirolimus
eluting coatings were at least as effective as -- and in some cases,
better -- than Johnson & Johnson's Cypher drug-eluting cardiovascular
stents. Based on these results, MIVT will begin preparations for human
implantation.
“MIV Therapeutics is developing a diverse
suite of polymer-free HAp coating formulas…
“The drug-eluting stent market grew from zero
to $5.3 billion in three years and has captured 85% of the US stent
market. To date, more than nine million DES devices have been inserted.
In 2005, about 1.5 million patients were implanted with drug-eluting
stents in the US alone...
“Despite a stock price increase of more than
50% since last Wednesday, in our view, MIVT, at a market cap of only $35
million, is still massively undervalued... MIV Therapeutics is paying
SISM Research $2,250 per month over a two-year period solely to ensure
independent coverage.”
SISM Research, based in Zurich, Switzerland, is a private investment
research firm offering high-quality, independent, fundamental research
on public companies since 1995. SISM writes, publishes and distributes
research coverage on micro- to small-cap public companies trading on the
OTC, NASDAQ and AMEX.
This coverage is geared toward institutional and individual investors in
both North America and in German-speaking Europe, a market that
represents more than 100 million people. SISM Research is a content
provider to Thomson Financials OneAnalytics/FirstCall and Investext, to
Reuters Multex, and Investrend.
Both SISM Research and Investrend Research subscribe to the “Standards
for Independent Research Providers” at http://www.firstresearchconsortium.com,
and MIVT’s research will be enrolled for
investor monitoring by the not-for-profit Shareholders Research
Alliance, Inc. (http://www.shareholdersresearch.com).
Anyone interested in receiving alerts regarding MIV Therapeutics
research should email contact@investrend.com
with "MIVT" in the subject line.
